Loading...
XNYS
BAX
Market cap9.53bUSD
Dec 05, Last price  
18.54USD
1D
0.32%
1Q
-24.08%
Jan 2017
-58.19%
Name

Baxter International Inc

Chart & Performance

D1W1MN
XNYS:BAX chart
P/E
P/S
0.90
EPS
Div Yield, %
4.69%
Shrs. gr., 5y
-0.35%
Rev. gr., 5y
-1.31%
Revenues
10.64b
-28.20%
9,849,000,00010,378,000,00011,263,000,00012,348,000,00012,562,000,00012,843,000,00013,893,000,00014,190,000,00015,259,000,00016,671,000,0009,968,000,00010,163,000,00010,561,000,00011,127,000,00011,362,000,00011,673,000,00012,784,000,00015,113,000,00014,813,000,00010,636,000,000
Net income
-649m
L
956,000,0001,396,000,0001,707,000,0002,014,000,0002,205,000,0001,420,000,0002,224,000,0002,326,000,0002,012,000,0002,497,000,000968,000,0004,965,000,000717,000,0001,624,000,0001,001,000,0001,102,000,0001,284,000,000-2,421,000,0002,656,000,000-649,000,000
CFO
1.02b
-40.96%
1,550,000,0002,183,000,0002,305,000,0002,515,000,0002,909,000,0003,003,000,0002,817,000,0003,106,000,0003,198,000,0003,215,000,0001,647,000,0001,624,000,0001,837,000,0002,096,000,0002,104,000,0001,868,000,0002,222,000,0001,211,000,0001,726,000,0001,019,000,000
Dividend
Aug 30, 20240.29 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
IPO date
May 15, 1961
Employees
60,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT